Cargando…

Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report

RATIONALE: Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Lijun, Wang, Lei, Zhu, Panrong, Xia, Youyou, Qiao, Yun, Hui, Kaiyuan, Hu, Chenxi, Ren, Yan, Jiang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708962/
https://www.ncbi.nlm.nih.gov/pubmed/29381963
http://dx.doi.org/10.1097/MD.0000000000008725
_version_ 1783282712147132416
author Liang, Lijun
Wang, Lei
Zhu, Panrong
Xia, Youyou
Qiao, Yun
Hui, Kaiyuan
Hu, Chenxi
Ren, Yan
Jiang, Xiaodong
author_facet Liang, Lijun
Wang, Lei
Zhu, Panrong
Xia, Youyou
Qiao, Yun
Hui, Kaiyuan
Hu, Chenxi
Ren, Yan
Jiang, Xiaodong
author_sort Liang, Lijun
collection PubMed
description RATIONALE: Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib is a novel and highly selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. There are no reports of concurrent apatinib with gemcitabine in patients with pancreatic cancer-mediated MA. PATIENT CONCERNS: Herein, we presented a 64-year-old man patient who visited hospital due to abdominal pain for 1 month. DIAGNOSES: He was initially diagnosed with pancreatic cancer and his first symptom was MA. INTERVENTIONS: After failing in tube drainage and gemcitabine therapy, the patient received gemcitabine combined apatinib orally and after administrated 1 month, the MA was evaluated as nearly clear response according to the RECIST 1.1 standard, and without further need of paracentesis. The CEA and CA199 reached the lowest level after administrating for 2.5 months during the treatment process. OUTCOMES: 10.5 months following apatinib administration, the patient achieved a progression-free survival for more than 11 months. Hypertension (grade IV), hand-foot syndrome (grade I) and proteinuria (grade II) were observed. LESSONS: It indicated that apatinib concurrent gemcitabine may be a superior choice for pancreatic cancer-mediated MA. Further clinical trials required to confirm its efficacy and safety.
format Online
Article
Text
id pubmed-5708962
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57089622017-12-07 Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report Liang, Lijun Wang, Lei Zhu, Panrong Xia, Youyou Qiao, Yun Hui, Kaiyuan Hu, Chenxi Ren, Yan Jiang, Xiaodong Medicine (Baltimore) 5700 RATIONALE: Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib is a novel and highly selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. There are no reports of concurrent apatinib with gemcitabine in patients with pancreatic cancer-mediated MA. PATIENT CONCERNS: Herein, we presented a 64-year-old man patient who visited hospital due to abdominal pain for 1 month. DIAGNOSES: He was initially diagnosed with pancreatic cancer and his first symptom was MA. INTERVENTIONS: After failing in tube drainage and gemcitabine therapy, the patient received gemcitabine combined apatinib orally and after administrated 1 month, the MA was evaluated as nearly clear response according to the RECIST 1.1 standard, and without further need of paracentesis. The CEA and CA199 reached the lowest level after administrating for 2.5 months during the treatment process. OUTCOMES: 10.5 months following apatinib administration, the patient achieved a progression-free survival for more than 11 months. Hypertension (grade IV), hand-foot syndrome (grade I) and proteinuria (grade II) were observed. LESSONS: It indicated that apatinib concurrent gemcitabine may be a superior choice for pancreatic cancer-mediated MA. Further clinical trials required to confirm its efficacy and safety. Wolters Kluwer Health 2017-11-27 /pmc/articles/PMC5708962/ /pubmed/29381963 http://dx.doi.org/10.1097/MD.0000000000008725 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Liang, Lijun
Wang, Lei
Zhu, Panrong
Xia, Youyou
Qiao, Yun
Hui, Kaiyuan
Hu, Chenxi
Ren, Yan
Jiang, Xiaodong
Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
title Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
title_full Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
title_fullStr Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
title_full_unstemmed Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
title_short Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report
title_sort apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: a case report
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708962/
https://www.ncbi.nlm.nih.gov/pubmed/29381963
http://dx.doi.org/10.1097/MD.0000000000008725
work_keys_str_mv AT lianglijun apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT wanglei apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT zhupanrong apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT xiayouyou apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT qiaoyun apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT huikaiyuan apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT huchenxi apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT renyan apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport
AT jiangxiaodong apatinibconcurrentgemcitabineforcontrollingmalignantascitesinadvancedpancreaticcancerpatientacasereport